Lifecore Biomedical, Inc. (LFCR) 股票分析

公司概述

Lifecore Biomedical, Inc. operates as an integrated contract development and manufacturing organization serving clients across the United States, Belgium, the Netherlands, and international markets. The company provides comprehensive services encompassing the development, manufacture, aseptic fill, and related pharmaceutical production processes. This entity functions within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on specialized pharmaceutical formulations and manufacturing capabilities rather than mass-market consumer drugs. As of the latest data, the company maintains a market capitalization of $176.89M and employs approximately 400 individuals to support its operations. The annual revenue recorded over the trailing twelve months stands at $129.46M, indicating a mid-sized enterprise within its niche. These valuation and revenue figures suggest that Lifecore Biomedical holds a specific position in the contract manufacturing landscape, balancing significant operational scale with a relatively modest market capitalization typical of specialty manufacturing firms that may not yet be fully scaled to large-cap status.

财务健康

Over the trailing twelve months, the company generated revenue of $129.46M, while reporting a net income loss of $34,503,432 and an EBITDA of $8.24M. The substantial gap between the positive revenue and the negative net income reveals a cost structure where operating expenses, likely including research and development or administrative costs, significantly outweigh the gross profits generated from sales. Although the free cash flow metric is listed as N/A in the available data, the company currently holds a cash balance of $17.47M against total debt of $141.28M. The gross margin stands at 31.4%, indicating that the company retains roughly one-third of its revenue after direct production costs, which is a moderate margin for the specialty manufacturing sector. The operating margin is reported at 8.2%, reflecting the efficiency of the company in managing overhead and administrative expenses relative to revenue. However, the profit margin is negative at -23.8%, highlighting that the net income losses are severe enough to drag profitability well below zero despite decent operational margins. The debt-to-equity ratio is an extreme 414.80, suggesting a highly leveraged balance sheet where debt obligations are vastly disproportionate to the company's equity base. In contrast, the current ratio of 3.49 indicates robust short-term liquidity, as current assets are more than three times current liabilities, providing a buffer against immediate financial obligations. Return on Equity and Return on Assets are both N/A, which prevents a direct assessment of management's effectiveness in generating returns on the shareholder's capital or the total asset base at this time.

估值评估

The trailing twelve-month P/E ratio is N/A due to the company's net losses, whereas the forward P/E is listed as -5.69, implying that the market expects continued earnings contraction or that earnings will not turn positive in the near term based on current analyst models. The price-to-book ratio is -12.45, a negative figure that indicates the market is valuing the company below its book value, often seen in distressed situations or firms with significant intangible assets not captured on the balance sheet. The price-to-sales ratio is 1.37, suggesting that investors are willing to pay over one dollar for every dollar of sales, which can be high for a loss-making firm but may reflect confidence in future contract wins. The enterprise value to EBITDA multiple is 42.34, a very high multiple that typically signals expensive valuation relative to cash earnings, potentially due to the scarcity of contract manufacturing peers or high growth expectations not yet realized. The stock has traded between a 52-week low of $3.63 and a 52-week high of $8.98, providing a historical range for price discovery. The beta value of 0.88 indicates that the stock's price volatility is slightly lower than the broader market, suggesting it may be less sensitive to general market swings compared to large-cap equities.

Growth & Income

The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A in the available facts, meaning historical growth rates cannot be quantified from the current dataset. In the absence of specific growth rates, it is impossible to determine if earnings are growing faster or slower than revenue; however, the negative earnings suggest a contraction in profitability relative to revenue generation. The company does not pay a dividend, as indicated by the N/A dividend yield and a payout ratio of 0.0%, which means the company reinvests all available earnings—or in this case, retains losses—into its operations rather than distributing cash to shareholders. This reinvestment strategy is typical for specialty manufacturers in the development phase that prioritize capital expenditure for manufacturing capacity over income distribution. The overall growth and income profile currently reflects a company that is generating revenue but struggling with profitability, with no current income generation for investors and undefined historical growth metrics based on the provided data.